Need professional-grade analysis? Visit stockanalysis.com
$24.38M
N/A
N/A
N/A
Neurosense Therapeutics Ltd (NRSN) trades on United States in USD. The company is classified in the Healthcare sector under the Pharmaceutical Preparations industry. The stock currently trades at $0.71, up 1.79% from the previous close.
Over the past year, NRSN has traded between a low of $0.69 and a high of $2.49. The stock has lost 28.5% over this period. It is currently 71.3% below its 52-week high.
Neurosense Therapeutics Ltd has a market capitalization of $24.38M.
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.
Side-by-side comparison against top Healthcare peers.